181 related articles for article (PubMed ID: 35741710)
21. MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy.
Li YL; Tang JM; Chen XY; Luo B; Liang GH; Qu Q; Lu ZY
Hum Cell; 2020 Jul; 33(3):610-618. PubMed ID: 32342278
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM
Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
24. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
25. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
26. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.
Yang T; Sim KY; Ko GH; Ahn JS; Kim HJ; Park SG
J Exp Clin Cancer Res; 2022 Mar; 41(1):82. PubMed ID: 35241148
[TBL] [Abstract][Full Text] [Related]
27. PKC-β/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.
Ma D; Liu P; Wang P; Zhou Z; Fang Q; Wang J
J Cell Physiol; 2021 Sep; 236(9):6312-6327. PubMed ID: 33561320
[TBL] [Abstract][Full Text] [Related]
28. Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.
Hirao T; Yamaguchi M; Kikuya M; Chibana H; Ito K; Aoki S
Cancer Sci; 2018 Jan; 109(1):121-131. PubMed ID: 29121435
[TBL] [Abstract][Full Text] [Related]
29. MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
Yap E; Norziha ZA; Simbun A; Tumian NR; Cheong SK; Leong CF; Wong CL
Leuk Res; 2017 Aug; 59():32-40. PubMed ID: 28544907
[TBL] [Abstract][Full Text] [Related]
30. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
[TBL] [Abstract][Full Text] [Related]
31. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J
Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755
[TBL] [Abstract][Full Text] [Related]
32. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
[TBL] [Abstract][Full Text] [Related]
33. Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia.
Patel KD; De M; Jethva DD; Rathod BS; Patel PS
Arch Med Res; 2022 Jan; 53(1):51-58. PubMed ID: 34275666
[TBL] [Abstract][Full Text] [Related]
34. LncRNA OIP5-AS1 Promotes the Autophagy-Related Imatinib Resistance in Chronic Myeloid Leukemia Cells by Regulating miR-30e-5p/ATG12 Axis.
Dai H; Wang J; Huang Z; Zhang H; Wang X; Li Q; Feng W
Technol Cancer Res Treat; 2021; 20():15330338211052150. PubMed ID: 34723728
[No Abstract] [Full Text] [Related]
35. Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.
Yin L; Xu J; Wu W; Niu M; Li Z; Zhu F; Xu K
Hematology; 2023 Dec; 28(1):2224625. PubMed ID: 37345979
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells.
Zhang J; Zhang M; Liang Y; Liu M; Huang Z
Hematology; 2022 Dec; 27(1):43-52. PubMed ID: 34957936
[No Abstract] [Full Text] [Related]
37. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
38. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.
Sinnakannu JR; Lee KL; Cheng S; Li J; Yu M; Tan SP; Ong CCH; Li H; Than H; Anczuków-Camarda O; Krainer AR; Roca X; Rozen SG; Iqbal J; Yang H; Chuah C; Ong ST
Leukemia; 2020 Jul; 34(7):1787-1798. PubMed ID: 32051529
[TBL] [Abstract][Full Text] [Related]
39. Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells.
Chen JY; Wang MC; Hung WC
J Cell Physiol; 2011 Feb; 226(2):407-13. PubMed ID: 20717963
[TBL] [Abstract][Full Text] [Related]
40. Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.
Tadesse F; Asres G; Abubeker A; Gebremedhin A; Radich J
JCO Glob Oncol; 2021 Jul; 7():1187-1193. PubMed ID: 34292760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]